Critical Care and Perioperative Implications of New Diabetic Medications

Concurrent Session Moderator(s)

• 

  Mona Patel, PharmD, FCCM, BCCCP

  NYU Langone Health

The uses of and indications for sodium-glucose transport protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) agonists have been increasing over the past several years. However, both classes carry risks for critically ill and perioperative patients and have created new and unique challenges for critical care clinicians, who may not be familiar with these medication classes because they are commonly used in outpatient settings or in stable hospitalized patients. Speakers will provide an overview of the pharmacology and indications of SLGT-2 inhibitors and GLP-1 agonists. Strategies for mitigating and managing associated risks and complications in critically ill and perioperative patients will be discussed.

Presentations:

• 9:50am – 10:05am Eastern Time

  Management of Sodium-Glucose Transport Protein 2 Inhibitors in Critically Ill Patients
  

  Adham Mohamed, PharmD, BCPS, BCCCP – Saint Luke's Hospital of Kansas City
• 10:05am – 10:20am Eastern Time

  Glucagon-Like Peptide-1 Agonist Risks and Complications in Critically Ill and Perioperative Patients
  

  Kunal Karamchandani, MD, FCCP, FCCM – UT Southwestern Medical Center
• 10:20am – 10:35am Eastern Time

  Leveraging Electronic Medical Records and Preoperative Clinics to Mitigate Risks Associated With SGLT-2 Inhibitors and GLP-1 Agonists in the Perioperative Setting
  

  Laura M. Ebbitt, PharmD (she/her/hers) – University of Kentucky HealthCare